$CBDW 1606 Corp. Target for Strategic Investment A
Post# of 37039
https://www.accesswire.com/941303/1606-corp-t...treatments
SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606" , a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of Adnexus's HIV and SARS-CoV-2 research.
Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.
The acquisition further strengthens Adnexus's position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, Adnexus is uniquely positioned to accelerate the development of high-impact therapies.
Austen Lambrecht, CEO of 1606 Corp., commented, "The merger between Adnexus Biotechnologies and Sanctum Therapeutics marks a pivotal moment in the fight against HIV and other infectious diseases. By combining Adnexus's cutting-edge AI-driven drug discovery platform with Sanctum's breakthrough therapies, they are not only advancing the development of life-saving treatments but also driving forward our mission to leverage technological innovation for the betterment of global healthcare. Lambrecht continued, "This strategic partnership underscores our commitment to supporting transformative biotech advancements, and we are excited to play a role in helping bring these therapies to market for those who need them most."
This synergistic combination of resources, along with Adnexus's cutting-edge Sutra AI Drug Discovery Platform, creates a powerful foundation for continued innovation and growth, ultimately delivering significant value for patients and shareholders alike.
Adnexus has recently executed a Letter of Intent with the Company for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.